May 19, 2013 11:39 AM ET

Healthcare Equipment and Supplies

Company Overview of Harvest Technologies Corporation

Company Overview

Harvest Technologies Corporation provides bone marrow aspirate concentrate (BMAC) systems to treat vascular, orthopedic, and cardiovascular diseases. It offers SmartPReP 2 APC+, a technology platform for the rapid preparation of autologous platelet concentrate; and SmartPReP 2 BMAC, a point-of-care tool that provides orthopedic surgeons access to the healing potential of autologous stem cells. The company also provides hardware systems, such as SMP-2, a SmartPReP 2 platelet concentrate system; WS-2, a SmartPReP2 BMAC workstation; BW-60, a reusable counter balance weight for SmartPReP 2; and BMAC and SmartPReP 2 BMAC procedure packs, and BMAC bone graft applicators. In addition, it offers Sma...

Detailed Description

40 Grissom Road

Suite 100

Plymouth, MA 02360

United States

Founded in 1995

Phone:

508-732-7500

Fax:

508-732-0400

www.harvesttech.com

Key Executives for Harvest Technologies Corporation

Co Founder
Co-Founder
Chief Financial Officer
Vice President of Operations
Vice President and General Manager of Strategic Business Development
Compensation as of Fiscal Year 2012.

Harvest Technologies Corporation Key Developments

Harvest Technologies Corporation Grants CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia

Harvest Technologies Corporation announced CE Marking for an expanded clinical indication for its SmartPReP(R) 2 Bone Marrow Aspiration Concentration System (BMAC(R) 2) product. The British Standards Institution (BSI), a notified body under the Medical Device Directive, has awarded a certificate indicating that the Harvest SmartPReP2 Bone Marrow Aspiration Concentrate System (BMAC2) is intended to be used at point-of-care for the safe and rapid preparation of autologous nucleated cell concentrate from Bone Marrow Aspiration (BMA) for administration into ischemic tissues of the affected limb due to No-Option Critical Limb Ischemia. This is the first time an autologous point-of-care cellular therapy company has presented sufficient clinical evidence for a notified body to grant approval to promote a specific product for this clinical use. This certification comes after BSI's extensive review of clinical data from nearly 50 clinical trials and investigations, including data using Harvest Technologies BMAC2 System. Previous studies have shown that critical limb ischemia (CLI) patients that have tissue loss (gangrenous or ulcer wounds) are at severe risk for amputation. Harvest studies have shown that the use of the BMAC2 system reduces that risk and is a viable option for limb salvage. The Harvest studies have also been able to show improvement in rest pain for patients with severe rest pain.

Similar Private Companies By Industry

Company Name Region
SynSonix, Inc. United States
Lumen Biomedical, Inc. United States
LifeSavings Technologies, LLC United States
Ornim, Inc. United States
Vantix Diagnostics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Harvest Technologies Corporation, please visit www.harvesttech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.